Silver Book Fact

“A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans age 65 and older with Alzheimer’s disease from 5.6 million to 4 million by 2020.  As a result, 1.6 million Americans who would be expected to have the condition in 2020 would be free of the condition.  In addition, five years later, in 2025, 2.7 million Americans–42 percent of the 6.5 million people who would be expected to have Alzheimer’s in that year–would be disease free.  The biggest effect would be in 2050 when 5.8 million people–43 percent of the 13.5 million Americans who would be expected to have Alzheimer’s without the breakthrough–would not have the condition.”

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is to treat Alzheimer’s disease. The medicine inhibits plaque formation and blocks the…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…  
  • The U.S. Food and Drug Administration has approved five drugs that temporarily improve Alzheimer’s disease symptoms.  
  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…